

Sensibility of metrotexate chemotherapy in human laryngeal squamous cell carcinoma hep²

Ana Livia Silva Galbiatti¹, Heloisa Cristina Caldas², João Armando Padovani Junior³, Érika Cristina Pavarino¹ and Eny Maria Goloni-Bertollo¹

¹Genetics and Molecular Biology Research Unit - UPGEM, FAMERP- São José do Rio Preto Medical School, Brazil

²Laboratory of Experimental Immunology and Transplantation / LITEX, FAMERP- São José do Rio Preto Medical School, Brazil

³Department of University São José do Rio Preto Medical School - FAMERP, Brazil

Folate plays a key role in one-carbon metabolism essential for the purine, pyrimidine and DNA biosynthesis. Methotrexate (MTX) is an antifolate chemotherapy that acts inhibiting purine and pyrimidine synthesis, which accounts for its efficacy in the cancer therapy. Sensibility of tumor cells to MTX is dose-related and it has impact on the therapeutic efficacy of treatment. We evaluated the response of treatment in Hep-2 laryngeal cancer cells to methotrexate (MTX) chemotherapy in vitro. For this, three different concentrations 0.25 μ M, 25 μ M, and 75 μ M of Metrotexate were added separately in Hep-2 cell lines plated in six-well culture plates for 24 hours at 37 °C. Cells sensibility was evaluated by double staining with fluorescein isothiocyanate (FITC) label Bcl-2 (100: sc-509) by Flow Cytometry Technique. Statistical analysis was performed by Chi square test (X²) to compare the cell viability. Correlation coefficient of Pearson (R²) between the concentrations also was measured. Our results showed that for the treatment with 0.25 μ M, 25.0 μ M and 75.0 μ M MTX concentration, the viable cells were 85.43%, 22.46% and 8.42%, respectively. There was positive association between the 0.25 mM (X²=55.001; p<0.0001), 25 mM (X²=2991.3; p<0.0001) and 75 mM (X²=5091.7; p<0.0001) MTX concentrations. There was a good correlation between cell viability and the different doses of the chemotherapy (R² = 0.9276). In conclusion, the higher the concentration of MTX chemotherapeutic is associated with lower sensitivity of tumor cells. There are a positive correlation between cell viability and the three different doses of the MTX chemotherapeutic.

Biography

Ana Livia Silva Galbiatti is a Biologist and Pharmaceutical, has completed his Master Degree in Health Sciences at FAMERP- São José do Rio Preto Medical School, São Paulo-Brazil (2010) and actually she is PhD student in the same University. She has published 14 papers in reputed journals and she is reviewer in some qualified journals.

analivia_sg@yahoo.com.br